• Product name

  • Purity

    70 - 90% by HPLC.

  • Animal free

  • Nature

    • Species

    • Predicted molecular weight

      33 kDa


Our Abpromise guarantee covers the use of ab97360 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications


  • Form

  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names

    • APY
    • ATOPY
    • B lymphocyte antigen CD20
    • B Lymphocyte Cell Surface Antigen B1
    • B-lymphocyte antigen CD20
    • B-lymphocyte cell-surface antigen B1
    • B-lymphocyte surface antigen B1
    • B1
    • Bp 35
    • Bp35
    • CD 20
    • CD20
    • CD20 antigen
    • CD20 receptor
    • CD20_HUMAN
    • CVID 5
    • CVID5
    • Fc epsilon receptor I beta chain
    • Fc Fragment of IgE high affinity I receptor for beta polypeptide
    • FCER1B
    • High affinity immunoglobulin epsilon receptor subunit beta
    • IgE Fc receptor subunit beta
    • IGEL
    • IGER
    • IGHER
    • LEU 16
    • Leu-16
    • LEU16
    • leukocyte surface antigen Leu 16
    • Leukocyte surface antigen Leu-16
    • Ly44
    • Membrane spanning 4 domains A1
    • Membrane spanning 4 domains subfamily A member 2
    • membrane-spanning 4-domains A1
    • Membrane-spanning 4-domains subfamily A member 1
    • MGC3969
    • MS4A1
    • MS4A2
    • S7
    see all
  • Function

    This protein may be involved in the regulation of B-cell activation and proliferation.
  • Tissue specificity

    Expressed on B-cells.
  • Involvement in disease

    Defects in MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5) [MIM:613495]; also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
  • Sequence similarities

    Belongs to the MS4A family.
  • Post-translational

    Phosphorylated. Might be functionally regulated by protein kinase(s).
  • Cellular localization

  • Information by UniProt


ab97360 has not yet been referenced specifically in any publications.

Customer reviews and Q&As


Thank you for contacting us.

Unfortunately, neither of these peptides overlap with the binding site recognized by Rituximab, which according to the reference PMID 16705086 bind to a discontiguous epitope comprised of amino acids 170-173 and 182-185 of human CD20. Because Rituximab recognizes an epitope shaped by a disulfide bond, it is likely that asynthetic peptidewill not be able to effectively block this antibody. You may be able to use purified CD20 to inhibit Rituximab activity. While we do not currently sell purified CD20, you may be able to find it by searching

I hope this helps, please let me know if you need any additional information.

Read More

For licensing inquiries, please contact

Sign up